Literature DB >> 27312238

A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K.

Iraia García-Santisteban1,2, Igor Arregi3, Marián Alonso-Mariño3, María A Urbaneja3, Juan J Garcia-Vallejo4, Sonia Bañuelos5, Jose A Rodríguez6.   

Abstract

The exportin CRM1 binds nuclear export signals (NESs), and mediates active transport of NES-bearing proteins from the nucleus to the cytoplasm. Structural and biochemical analyses have uncovered the molecular mechanisms underlying CRM1/NES interaction. CRM1 binds NESs through a hydrophobic cleft, whose open or closed conformation facilitates NES binding and release. Several cofactors allosterically modulate the conformation of the NES-binding cleft through intramolecular interactions involving an acidic loop and a C-terminal helix in CRM1. This current model of CRM1-mediated nuclear export has not yet been evaluated in a cellular setting. Here, we describe SRV100, a cellular reporter to interrogate CRM1 nuclear export activity. Using this novel tool, we provide evidence further validating the model of NES binding and release by CRM1. Furthermore, using both SRV100-based cellular assays and in vitro biochemical analyses, we investigate the functional consequences of a recurrent cancer-related mutation, which targets a residue near CRM1 NES-binding cleft. Our data indicate that this mutation does not necessarily abrogate the nuclear export activity of CRM1, but may increase its affinity for NES sequences bearing a more negatively charged C-terminal end.

Entities:  

Keywords:  Cellular assay; Chronic lymphocytic leukemia; NES; Recurrent mutation; XPO1

Mesh:

Substances:

Year:  2016        PMID: 27312238     DOI: 10.1007/s00018-016-2292-0

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  53 in total

1.  CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin.

Authors:  Jose A Rodríguez; Simone W Span; Carlos G M Ferreira; Frank A E Kruyt; Giuseppe Giaccone
Journal:  Exp Cell Res       Date:  2002-04-15       Impact factor: 3.905

2.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.

Authors:  Xose S Puente; Magda Pinyol; Víctor Quesada; Laura Conde; Gonzalo R Ordóñez; Neus Villamor; Georgia Escaramis; Pedro Jares; Sílvia Beà; Marcos González-Díaz; Laia Bassaganyas; Tycho Baumann; Manel Juan; Mónica López-Guerra; Dolors Colomer; José M C Tubío; Cristina López; Alba Navarro; Cristian Tornador; Marta Aymerich; María Rozman; Jesús M Hernández; Diana A Puente; José M P Freije; Gloria Velasco; Ana Gutiérrez-Fernández; Dolors Costa; Anna Carrió; Sara Guijarro; Anna Enjuanes; Lluís Hernández; Jordi Yagüe; Pilar Nicolás; Carlos M Romeo-Casabona; Heinz Himmelbauer; Ester Castillo; Juliane C Dohm; Silvia de Sanjosé; Miguel A Piris; Enrique de Alava; Jesús San Miguel; Romina Royo; Josep L Gelpí; David Torrents; Modesto Orozco; David G Pisano; Alfonso Valencia; Roderic Guigó; Mónica Bayés; Simon Heath; Marta Gut; Peter Klatt; John Marshall; Keiran Raine; Lucy A Stebbings; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Ivo Gut; Armando López-Guillermo; Xavier Estivill; Emili Montserrat; Carlos López-Otín; Elías Campo
Journal:  Nature       Date:  2011-06-05       Impact factor: 49.962

3.  Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1.

Authors:  Qingxiang Sun; Yazmin P Carrasco; Youcai Hu; Xiaofeng Guo; Hamid Mirzaei; John Macmillan; Yuh Min Chook
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-07       Impact factor: 11.205

4.  Nucleocytoplasmic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signal.

Authors:  Roland H Stauber; Uta Rabenhorst; Alexander Rekik; Knut Engels; Carolin Bier; Shirley K Knauer
Journal:  Traffic       Date:  2006-09-19       Impact factor: 6.215

5.  Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.

Authors:  Parvathi Ranganathan; Xueyan Yu; Caroline Na; Ramasamy Santhanam; Sharon Shacham; Michael Kauffman; Alison Walker; Rebecca Klisovic; William Blum; Michael Caligiuri; Carlo M Croce; Guido Marcucci; Ramiro Garzon
Journal:  Blood       Date:  2012-06-07       Impact factor: 22.113

6.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

7.  CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.

Authors:  Hiromi Inoue; Michael Kauffman; Sharon Shacham; Yosef Landesman; Joy Yang; Christopher P Evans; Robert H Weiss
Journal:  J Urol       Date:  2012-10-16       Impact factor: 7.450

8.  Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.

Authors:  Aiguo Shen; Yuchan Wang; Yueming Zhao; Lin Zou; Linlin Sun; Chun Cheng
Journal:  Neurosurgery       Date:  2009-07       Impact factor: 4.654

9.  Electrostatic interactions involving the extreme C terminus of nuclear export factor CRM1 modulate its affinity for cargo.

Authors:  Abigail M Fox; Danguole Ciziene; Stephen H McLaughlin; Murray Stewart
Journal:  J Biol Chem       Date:  2011-06-27       Impact factor: 5.157

Review 10.  Allosteric control of the exportin CRM1 unraveled by crystal structure analysis.

Authors:  Thomas Monecke; Achim Dickmanns; Ralf Ficner
Journal:  FEBS J       Date:  2014-06-06       Impact factor: 5.542

View more
  10 in total

1.  Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.

Authors:  Justin Taylor; Maria Sendino; Alexander N Gorelick; Alessandro Pastore; Matthew T Chang; Alexander V Penson; Elena I Gavrila; Connor Stewart; Ella M Melnik; Florisela Herrejon Chavez; Lillian Bitner; Akihide Yoshimi; Stanley Chun-Wei Lee; Daichi Inoue; Bo Liu; Xiao J Zhang; Anthony R Mato; Ahmet Dogan; Michael G Kharas; Yuhong Chen; Demin Wang; Rajesh K Soni; Ronald C Hendrickson; Gorka Prieto; Jose A Rodriguez; Barry S Taylor; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2019-07-08       Impact factor: 39.397

2.  Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).

Authors:  Misako Nagasaka; Mohammad Fahad B Asad; Mohammed Najeeb Al Hallak; Md Hafiz Uddin; Ammar Sukari; Yasmine Baca; Joanne Xiu; Dan Magee; Hirva Mamdani; Dipesh Uprety; Chul Kim; Bing Xia; Stephen V Liu; Jorge J Nieva; Gilberto Lopes; Gerold Bepler; Hossein Borghaei; Michael J Demeure; Luis E Raez; Patrick C Ma; Sonam Puri; W Michael Korn; Asfar S Azmi
Journal:  Lung Cancer       Date:  2021-08-27       Impact factor: 6.081

Review 3.  The nuclear export protein XPO1 - from biology to targeted therapy.

Authors:  Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal:  Nat Rev Clin Oncol       Date:  2020-11-10       Impact factor: 66.675

Review 4.  Karyopherin-mediated nucleocytoplasmic transport.

Authors:  Casey E Wing; Ho Yee Joyce Fung; Yuh Min Chook
Journal:  Nat Rev Mol Cell Biol       Date:  2022-01-20       Impact factor: 113.915

Review 5.  XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.

Authors:  Vincent Camus; Hadjer Miloudi; Antoine Taly; Brigitte Sola; Fabrice Jardin
Journal:  J Hematol Oncol       Date:  2017-02-14       Impact factor: 17.388

Review 6.  Small Molecule Inhibitors of CRM1.

Authors:  Bibiana I Ferreira; Bastien Cautain; Inês Grenho; Wolfgang Link
Journal:  Front Pharmacol       Date:  2020-05-07       Impact factor: 5.810

7.  Specific inhibition of the Survivin-CRM1 interaction by peptide-modified molecular tweezers.

Authors:  Annika Meiners; Sandra Bäcker; Inesa Hadrović; Christian Heid; Christine Beuck; Yasser B Ruiz-Blanco; Joel Mieres-Perez; Marius Pörschke; Jean-Noël Grad; Cecilia Vallet; Daniel Hoffmann; Peter Bayer; Elsa Sánchez-García; Thomas Schrader; Shirley K Knauer
Journal:  Nat Commun       Date:  2021-03-08       Impact factor: 14.919

8.  Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification.

Authors:  Ting Liu; Jianan Rao; Wenting Hu; Bowen Cui; Jiaoyang Cai; Yuhan Liu; Huiying Sun; Xiaoxiao Chen; Yanjing Tang; Jing Chen; Xiang Wang; Han Wang; Wubin Qian; Binchen Mao; Sheng Guo; Ronghua Wang; Yu Liu; Shuhong Shen
Journal:  Nat Commun       Date:  2022-03-28       Impact factor: 17.694

9.  Inhibition of chromosomal region maintenance 1 suppresses the migration and invasion of glioma cells via inactivation of the STAT3/MMP2 signaling pathway.

Authors:  Qianqian Shan; Shengsheng Li; Qiyu Cao; Chenglong Yue; Mingshan Niu; Xiangyu Chen; Lin Shi; Huan Li; Shangfeng Gao; Jun Liang; Rutong Yu; Xuejiao Liu
Journal:  Korean J Physiol Pharmacol       Date:  2020-05-01       Impact factor: 2.016

10.  Selective Disruption of Survivin's Protein-Protein Interactions: A Supramolecular Approach Based on Guanidiniocarbonylpyrrole.

Authors:  Dennis Aschmann; Cecilia Vallet; Sunil K Tripathi; Yasser B Ruiz-Blanco; Max Brabender; Carsten Schmuck; Elsa Sanchez-Garcia; Shirley K Knauer; Michael Giese
Journal:  Chembiochem       Date:  2022-01-18       Impact factor: 3.461

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.